Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma

1 Nov 2024

Abstract excerpt

BACKGROUND: The child cancer, neuroblastoma (NB), is characterised by a low incidence of mutations and strong oncogenic embryonal driver signals. Many new targeted epigenetic modifier drugs have failed in human trials as monotherapy. METHODS: We performed a high-throughput, combination chromatin-modifier drug screen against NB cells. We screened 13 drug candidates in 78 unique combinations. RESULTS: We found that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Epigenetics and DNA Methylation
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39501501
DOI: 10.1002/cam4.70082

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastomaPMID 39501501Read ↗

Increased Efficacy of Histone Methyltransferase G9a Inhibitors Against MYCN-Amplified NeuroblastomaSemantic proximity Read ↗

Increased efficacy of histone methyltransferase G9a inhibitors against MYCN-amplified NeuroblastomaSemantic proximity Read ↗

Neuroblastoma treatment in the post-genomic eraSemantic proximity Read ↗

Review: Targeting EZH2 in neuroblastomaSemantic proximity Read ↗

Neuroblastoma and the epigenomeSemantic proximity Read ↗

Epigenetic Dysregulation in MYCN-Amplified NeuroblastomaSemantic proximity Read ↗

EZH2 inhibition enhances NK cell-mediated cytotoxicity and potentiates anti-GD2 immunotherapy in neuroblastomaSemantic proximity Read ↗

CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2Semantic proximity Read ↗

Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteomeSemantic proximity Read ↗

DHODH is an independent prognostic marker and potent therapeutic target in neuroblastomaSemantic proximity Read ↗

The biology of novel dual histone methyltransferase inhibitorsSemantic proximity Read ↗

Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.